19.89

3.26% -0.67

After Hours: 19.89

Lb Pharmaceuticals Inc (LBRX)

Overview News Price History Discussions Forecast

Lb Pharmaceuticals Inc stock is traded at $19.89, with a volume of 226.24K. It is down -3.26% in the last 24 hours and up +2.00% over the past month. LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.

Previous Close:

$20.56

Open:

$20.13

24h Volume:

226.24K

Relative Volume:

0.88

Market Cap:

$503.20M

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

-7.49%

1M Performance:

+2.00%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1-Day Range:

$19.70

$20.93

1-Week Range:

$19.38

$23.11

52-Week Range:

$13.36

$23.15

Lb Pharmaceuticals Inc Stock (LBRX) Company Profile

Name

Lb Pharmaceuticals Inc

Sector

Healthcare (1114)

Industry

Biotechnology (625)

Phone

917-450-6581

Address

575 MADISON AVENUE, NEW YORK

Employee

Twitter

Next Earnings Date

Latest SEC Filings

LBRX's Discussions on Twitter

Compare LBRX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LBRX Lb Pharmaceuticals Inc	19.89	520.15M	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	468.38	113.87B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	776.54	80.22B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	406.40	52.56B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	803.74	49.31B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	175.07	37.37B	447.02M	-1.18B	-906.14M	-6.1812

Lb Pharmaceuticals Inc Stock (LBRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-06-25	Initiated	Leerink Partners	Outperform
Oct-06-25	Initiated	Piper Sandler	Overweight
Oct-06-25	Initiated	Stifel	Buy

Lb Pharmaceuticals Inc Stock (LBRX) Latest News

Jan 06, 2026

LB Pharmaceuticals Appoints Ellen Rose and Lindsay Beaupre as Senior Vice Presidents - citybiz

Jan 06, 2026

LB Pharmaceuticals appoints two executives to leadership team By Investing.com - Investing.com Canada

Jan 06, 2026

LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture - The Manila Times

Jan 06, 2026

Jan 04, 2026

Schizophrenia drug developer LB Pharma jumps in trading debut - MSN

Jan 04, 2026

Jan 02, 2026

LB Pharmaceuticals (NASDAQ:LBRX) Stock Price Down 7.7%Should You Sell? - MarketBeat

Jan 02, 2026

Dec 31, 2025

LB Pharmaceuticals (NASDAQ:LBRX) Trading Up 3.8%Here's Why - MarketBeat

Dec 31, 2025

Dec 23, 2025

Top financings 2025 - BioWorld MedTech

Dec 23, 2025

LB Pharmaceuticals Inc (NASDAQ:LBRX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat

Dec 23, 2025

Dec 21, 2025

LB Pharmaceuticals Inc(NasdaqGM: LBRX) added to S&P TMI Index - marketscreener.com

Dec 21, 2025

Dec 19, 2025

Aktis Oncology files for US IPO as biotech listings rebound - 1470 & 100.3 WMBD

Dec 19, 2025

Pai Panandiker Kaya Kamlesh Net Worth (2025) - GuruFocus

Dec 19, 2025

Dec 18, 2025

LB Pharmaceuticals Inc(NasdaqGM: LBRX) added to Russell 3000 Index - marketscreener.com

Dec 18, 2025

LB Pharmaceuticals Inc(NasdaqGM: LBRX) added to Russell 2000 Index - marketscreener.com

Dec 18, 2025

Dec 15, 2025

LB Pharmaceuticals (NASDAQ:LBRX) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says - MarketBeat

Dec 11, 2025

Lexicon publishes preclinical data validating ACSL5 as obesity target By Investing.com - Investing.com Nigeria

Dec 11, 2025

Dec 10, 2025

LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Dec 10, 2025

LB Pharmaceuticals (Nasdaq: LBRX) issues inducement equity grant to incoming CCO - Stock Titan

Dec 10, 2025

LB Pharmaceuticals (LBRX) Stock Analysis Report | Financials & Insights - Benzinga

Dec 10, 2025

Lexicon publishes preclinical data validating ACSL5 as obesity target - Investing.com

Dec 10, 2025

LB Pharmaceuticals Added to the Russell 2000 and Russell 3000 Indices - marketscreener.com

Dec 10, 2025

Dec 09, 2025

LB Pharmaceuticals (NASDAQ:LBRX) Trading Down 4.8%Here's Why - MarketBeat

Dec 09, 2025

LB Pharmaceuticals Added to Russell 2000, 3000 Indices - marketscreener.com

Dec 09, 2025

LB Pharmaceuticals to join Russell 2000 and Russell 3000 indices - Investing.com

Dec 09, 2025

LB Pharmaceuticals to join Russell 2000 and Russell 3000 indices By Investing.com - Investing.com Canada

Dec 09, 2025

LB Pharmaceuticals Added to the Russell 2000® and Russell 3000® Indices - marketscreener.com

Dec 09, 2025

Dec 08, 2025

LB Pharmaceuticals (NASDAQ:LBRX) Trading Up 6.2%Still a Buy? - MarketBeat

Dec 08, 2025

Dec 06, 2025

LB Pharmaceuticals (NASDAQ:LBRX) Hits New 52-Week HighHere's What Happened - MarketBeat

Dec 06, 2025

Dec 03, 2025

LBRX: $300M IPO funds phase III schizophrenia and phase II bipolar depression trials, with 2027 data expected - TradingView

Dec 03, 2025